Publication:
Diagnosis and Treatment of High-Grade Astrocytoma

dc.contributor.authorSith Sathornsumeteeen_US
dc.contributor.authorJeremy N. Richen_US
dc.contributor.authorDavid A. Reardonen_US
dc.contributor.otherDuke University School of Medicineen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-08-24T01:59:17Z
dc.date.available2018-08-24T01:59:17Z
dc.date.issued2007-11-01en_US
dc.description.abstractHigh-grade astrocytomas include the most common adult central nervous system (CNS) tumor, glioblastoma multiforme, and anaplastic astrocytoma-a highly aggressive cancer with short median survival despite maximal multimodality therapy. Diagnosis is by clinical and radiographic findings confirmed by histopathology. Standard-of-care therapy includes surgical resection, radiotherapy, and temozolomide. Nearly all patients who have high-grade astrocytomas develop tumor recurrence or progression after this multimodality treatment. Two treatment challenges are molecular/genetic heterogeneity of tumors and limited CNS tumor delivery. It is probable that targeted therapies will be most effective in combination with one another or with cytotoxic therapies. This article discusses diagnosis and current treatment of high-grade astrocytomas. © 2007 Elsevier Inc. All rights reserved.en_US
dc.identifier.citationNeurologic Clinics. Vol.25, No.4 (2007), 1111-1139en_US
dc.identifier.doi10.1016/j.ncl.2007.07.004en_US
dc.identifier.issn07338619en_US
dc.identifier.other2-s2.0-35348962671en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/24695
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=35348962671&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleDiagnosis and Treatment of High-Grade Astrocytomaen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=35348962671&origin=inwarden_US

Files

Collections